Meeting
2016 ASCO Annual Meeting
Validation of a genomic risk classifier to predict prostate cancer-specific mortality (PCSM) in high-risk patients.
Authors
Jeffrey Karnes
Mayo Clinic, Rochester, MN
Jeffrey Karnes , Ashley Ross , Edward M. Schaeffer , Eric A. Klein , Nicholas Erho , Kasra Yousefi , Mandeep Takhar , Elai Davicioni , Bruce J. Trock
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Epidemiology/Outcomes
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5056)
DOI
10.1200/JCO.2016.34.15_suppl.5056
Abstract #
5056
Poster Bd #
313
Abstract Disclosures
Similar Posters
Poster
2013 Genitourinary Cancers Symposium
A genomic classifier independently prognostic of prostate cancer death in a high-risk surgical cohort.
First Author: Matthew R. Cooperberg
Poster
2021 ASCO Annual Meeting
Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).
First Author: Alan Dal Pra
Poster
2018 Genitourinary Cancers Symposium
Results of a phase II trial of neoadjuvant abiraterone + prednisone+ enzalutamide + leuprolide (APEL) versus enzalutamide + leuprolide (EL) for patients with high-risk localized prostate cancer (PC) undergoing radical prostatectomy (RP).
First Author: Rana R. McKay
Poster
2018 Genitourinary Cancers Symposium
Impact of genomic risk scores on treatment decisions following radical prostatectomy in a prospective Medicare registry.
First Author: John L. Gore